trial natriuretic factor (ANF) is a peptide hormone secreted from the cardiac atria. 12 The peptide is stored in the atrial myocytes in granules as a 126-amino-acid prohormone ANF .3'4 On secretion, this prohormone is split into an N-terminal moiety called N-terminal proANF [ANF ] and the biologically active ANF hormone [ANF(99-126)] in equimolar amounts. [5] [6] [7] After its secretion, ANF is rapidly cleared (half-life of 2.5 minutes8) from plasma by specific binding to abundant peripheral receptors9 and, to some extent, by enzymatic degradation. 10 Because of a longer half-life (in rat, eight times that of ANF),6 the plasma concentration of N-terminal proANF is up to 50 times higher than that of ANF. [5] [6] [7] 11 Correspondingly, plasma N-terminal proANF may better reflect subacute and chronic levels of atrial peptide secretion, but it may not be as sensitive as ANF to rapid fluctuations in secretion. Another major difference between ANF and N-terminal proANF is their stability and ease of measurement. N-terminal proANF is a stable substance that can be measured directly in plasma, whereas ANF loses some of its activity despite storage at -80°C and requires chromatographic extraction before measurement.5 12, 13 The major known stimulus for secretion of the atrial peptides is increased atrial wall stress, usually described as increased atrial stretch.14,15 Elevated plasma concentrations of both ANF and N-terminal proANF have been observed in patients with cardiac disease, with this increase proportional to the degree of clinical and hemodynamic deterioration.11 '16'17 In patients with New York Heart Association class II to IV heart failure, increased plasma concentrations of ANF have been associated with poor long-term prognosis.18 '19 A similar relation has been found in patients after acute myocardial infarction .20 In an elderly population, high ANF plasma levels have been associated with increased risk of development of congestive heart failure. 21 The Survival and Ventricular Enlargement (SAVE) study22 provided an excellent opportunity to examine the prognostic value of atrial peptides measured around the time of hospital discharge in patients at high risk after infarction -those with left ventricular dysfunction but no overt heart failure. Furthermore, it enabled us to assess whether, because of its stability and longer half-life, N-terminal proANF was superior to ANF as a prognostic indicator. To determine the independent The prospectively defined measures of outcome were mortality from all causes, mortality from cardiovascular causes, development of severe heart failure (congestive heart failure requiring ACE inhibition or hospitalization), and the combined end point of cardiovascular mortality or development of severe heart failure.
The relation between each of the specified end points and N-terminal proANF was investigated by both univariate and multivariate analyses using a Cox proportional hazard regression model. The assumption of a constant hazard ratio over time for the Cox regression model was tested and verified. The 
Results
Of the 534 patients who took part in the SAVE neurohormonal substudy,24 sufficient plasma for N-terminal proANF measurement was available in 246. Apart from a lower incidence of the risk factor hypertension and of the combined end point cardiovascular death or severe heart failure, the studied population appeared to be representative of the neurohormonal substudy patients as well as of the entire SAVE population (Table 1 Table 2 , there was a significant univariate relation between N-terminal proANF and a number of these variables. The N-terminal proANF plasma concentration was positively related to age; Killip class; systolic blood pressure at the time of randomization; the occurrence of atrial arrhythmias, transitory heart failure, prior myocardial infarction, diabetes, hypertension, or other location infarct (as opposed to anterior); and use of diuretics and digoxin. It was inversely related to LVEF, peak creatine kinase, and the occurrence of male gender, anterior infarct location (as opposed to other), and thrombolytic treatment. The ANF plasma concentration showed similar but weaker relations to eight of these variables.
Controlling for all specified demographic and clinical variables at baseline in multivariate analysis, age (13 Fig 1, where life-table curves for four of these end points are constructed after separating patients into N-terminal proANF quartiles.
N-terminal proANF and ANF levels were higher in all groups of patients with an event (Table 3) . To compare the predictive power of N-terminal proANF with that of ANF, a Cox proportional hazards model was constructed that included both N-terminal proANF and ANF levels ( Table 3) . Controlling for the level of ANF, it was found that N-terminal proANF was significantly related to each of the end points. On the other hand, after controlling for the effect of N-terminal proANF, the ANF level was not related to any of the five end points. Evidently, among the two neurohormones N-terminal proANF was the stronger predictor of all the five end points studied.
When N-terminal proANF was added to a multivariate model of clinical and laboratory variables known to influence survival (Table 4) , it was found to be a powerful independent predictor of long-term outcome. By multivariate analyses, N-terminal proANF was independently related to death, cardiovascular death, 1-year cardiovascular death, severe heart failure, and cardiovascular death or severe heart failure ( Table 4) . For the combined end point of cardiovascular death or severe heart failure, N-terminal proANF was the best clinical or laboratory predictor, even superior to age, LVEF, and prior myocardial infarction.
To compare the predictive power of N-terminal proANF with that of the other neurohormones in multivariate analysis, these variables were also included in the model (Table 5 ). The superior prognostic value of N-terminal proANF over these other neurohormones (ANF, norepinephrine, plasma renin activity, and arginine vasopressin) was evident in that while N-terminal proANF retained its significant relation to all the end points, only norepinephrine showed a significant relation and only to the end points severe heart failure and the combination cardiovascular death or severe heart failure. With respect to these end points, however, norepinephrine was a considerably weaker predictor than N-terminal proANF as evidenced from the Wald X2 values.
Discussion
The present study indicates that N-terminal proANF measured after myocardial infarction is a powerful neurohormonal predictor of subsequent cardiovascular events in patients with left ventricular dysfunction after infarction. The prognostic power of N-terminal proANF was particularly evident for the development of severe heart failure and the combined end point of severe heart failure or cardiovascular death. For these end points, N-terminal proANF was not only the most powerful neurohormonal predictor, it was also by far the best predictor of all clinical or laboratory variables included in the analysis.
Compared with the population examined in the main SAVE study, the presently studied subgroup showed a tendency toward a lesser incidence of prior myocardial infarction and diabetes and a significant reduction in the incidence of hypertension. This may have contributed to the slightly lower incidence of the combined end point cardiovascular death or severe heart failure and illustrates that the studied population was not entirely representative of the overall SAVE population.
There was a fairly large spread in time between the infarction and blood sampling (3 to 16 days). However, the blood for neurohormonal measurement was sampled just before randomization for the main SAVE study when the patients were clinically stable and without overt heart failure symptoms. This may explain why the spread in sampling time points did not obscure the relation of N-terminal proANF to prognosis. This is the first large-scale study evaluating the longterm prognostic value of neurohormonal activation measured around the time of hospital discharge postin- possible that diastolic dysfunction itself after infarction is a poor prognostic sign. Or, alternatively, as increasing filling pressures are a major stimulus for eccentric ventricular hypertrophy,30 increased atrial pressures may be a marker of patients at risk of ventricular dilatation after infarction. Ventricular dilatation after infarction is known to be a major if not the major independent predictor of mortality after infarction.3' N-terminal proANF fared considerably better than ANF as a prognostic indicator. This was an unexpected finding considering the assumed equimolar secretion of the two peptides. The difference may be explained by the longer half-life of N-terminal proANF, making it a better integrator over time of atrial peptide secretion. Another important and probably highly relevant difference between the peptides is the in vitro stability. Although ANF is known to be subject to in vitro degradation possibly even under -80°C of storage, '3 experiments in our laboratory indicate that N-terminal proANF immunoreactivity is well preserved after storage for as long as 3 days at room temperature and 2 years at -80°C (unpublished data). The peptide has also been found resistant to at least two repeated freezing-and-thawing cycles.
Information pertaining to the prognosis of patients after myocardial infarction is important in the selection of patients for different treatment regimens. LVEF is known to be a strong predictor of long-term outcome postinfarction31 and has been used to identify high-risk patients, those most likely to benefit from interventions designed to prolong survival. 
